Company intelligence / Profile preview
Medera Group
- Ownership
- Private
- Development stage
- Other
Overview
Medera is a clinical-stage biopharmaceutical company developing next-generation AAV-based cardiac gene therapies delivered via a proprietary intracoronary infusion method, supported by its human mini-Heart platform. Its lead programs SRD-001 (HFrEF), SRD-002 (HFpEF, Fast Track), and SRD-003 (DMD-associated cardiomyopathy, Orphan Drug) are in ongoing Phase 1/2a trials with early data from SRD-001 and SRD-002 showing clinically meaningful improvements in cardiac function and patient status.[1][2][3][4]
- Therapeutic areas
- CardiovascularPulmonology
- Modalities
- Gene therapyCell therapySmall moleculeBiologic
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Medera Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medera Group.